Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib and Famitinib in ER+/HER2- Advanced Breast Cancer
NCT05103826Phase 1Terminated
- Sponsor
- Hengrui
- Start
- Oct 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalpiciclib and famitinib in breast cancer, sponsored by Hengrui. Primary endpoints: Dose Limiting Toxicity at 28 days and Recommended Phase II Dose at 28 days. Started Oct 2021; status: terminated.
02
Drugs
dalpiciclibfamitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05103826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05103826.